MoonLake Immunotherapeutics Reports Q2 Results; Positive Phase 3 Topline

What Happened

• On August 10, 2026, MoonLake Immunotherapeutics (MLTX) issued a press release — furnished on Form 8‑K (Exhibit 99.1) — announcing financial results for the quarter ended June 30, 2026 and disclosing positive topline week‑16 results from its Phase 3 IZAR‑1 trial of sonelokimab (SLK) in psoriatic arthritis (PsA). The release was also provided under Regulation FD to ensure broad public disclosure.

Key Details

• Date filed: August 10, 2026 (Form 8‑K, Items 2.02 and 7.01).
• Quarter covered: financial results for the quarter ended June 30, 2026 were announced (see press release for figures).
• Clinical milestone: positive week‑16 topline results reported from the Phase 3 IZAR‑1 trial of sonelokimab (SLK) in PsA.
• Exhibit furnished: Press Release dated August 10, 2026 (Exhibit 99.1) was attached to the filing.

Why It Matters

• The combination of quarterly results and a positive Phase 3 topline announcement is material for investors: the clinical readout is a key development milestone for sonelokimab’s PsA program, and the financial update provides recent company performance context. Both items are likely to be monitored by shareholders for impact on future clinical, regulatory and commercial planning. Investors should read the full press release (Exhibit 99.1) for the detailed financial figures and full trial results.